Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00984919 · ClinicalTrials.gov registry record
Biomarker 11-dh-TXB2 in Blood and Urine Samples From Patients With Prostate Cancer and Healthy Volunteers
A clinical trial, sponsored by Barbara Ann Karmanos Cancer Institute.
- Completed
- Registry status
- 10
- Enrollment target
NCT00984919 is a clinical trial that has completed, run by Barbara Ann Karmanos Cancer Institute. The registered enrollment target is 10 participants.
The verdict
NCT00984919 has completed, sponsored by Barbara Ann Karmanos Cancer Institute.
- COMPLETED
- Registry status
- 10 participants
- Enrollment target
Study Summary
RATIONALE: Studying samples of blood and urine from patients with cancer in the laboratory may help doctors identify biomarkers related to cancer. PURPOSE: This research study is looking at a biomarker, 11-dh-TXB2, in blood and urine samples from patients with prostate cancer and healthy volunteers.
Interventions
- OTHER laboratory biomarker analysis
- OTHER high performance liquid chromatography
- OTHER mass spectrometry
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2009-11 |
| Est. Completion | 2011-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00984919
The ClinicalTrials.gov registry entry for NCT00984919 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Barbara Ann Karmanos Cancer Institute, which has 139 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT00984919 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00984919 about?
NCT00984919 is a clinical study titled "Biomarker 11-dh-TXB2 in Blood and Urine Samples From Patients With Prostate Cancer and Healthy Volunteers". RATIONALE: Studying samples of blood and urine from patients with cancer in the laboratory may help doctors identify biomarkers related to cancer. PURPOSE: This research study is looking at a biomarker, 11-dh-TXB2, in blood and urine samples from patients with prostate cancer and healthy volunteers...
What is the current status of trial NCT00984919?
This trial is currently completed. The enrollment target is 10 participants. The study started on 2009-11. Estimated completion is 2011-02.
What interventions are being tested in trial NCT00984919?
The interventions under investigation include: laboratory biomarker analysis (OTHER), high performance liquid chromatography (OTHER), mass spectrometry (OTHER).
Who is sponsoring clinical trial NCT00984919?
This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.